赵博士神经肌病领域进展专栏
转载请注明来自丁香园
发布日期: 2005-07-02 17:24
关键词: 肌病 点击次数:

Myasthenia gravis patients with low plasma IL-6 and IFN-gamma benefit from etanercept treatment.
Tuzun E, Meriggioli MN, Rowin J, Yang H, Christadoss P.

Steroid-dependent myasthenia gravis patients improved following treatment with etanercept (recombinant human TNF receptor:Fc) in a prospective pilot trial. While the plasma anti-acetylcholine receptor antibody levels remained unaffected, etanercept treatment increased plasma levels of C3, circulating immune complexes, IL-10 and IFN-gamma. There was a direct correlation between plasma IL-6, TNF-alpha and IFN-gamma levels and the post-treatment clinical scores of patients. Moreover, patients with lower pre-treatment plasma IL-6 and IFN-gamma levels attained better clinical improvement following etanercept treatment.

重症肌无力血清IL-6和IFN-gamma低者可通过依那西普治疗获益
一项前瞻性开放性研究表明,激素依赖性重症肌无力病人应用依那西普(TNF-α拮抗剂, etanercept )后症状可改善。但血清乙酰胆碱受体抗体水平却无明显变化,依那西普可提高血浆补体C3水平、循环免疫复合物、IL-10和IFN-gamma。血浆IL-6、TNF-alpha和IFN-gamma水平与治疗后的临床评分有直接相关。此外,治疗前IL-6和IFN-gamma水平低者获得的治疗效果更佳。
J Autoimmun. 2005 May;24(3):261-8.

< 上一页 下一页 >
分页: [1 ]   [2 ]   [3 ]   [4 ]   [5 ]   [6 ]   [7]   [8 ]   [9 ]   [10 ]  

请点这里参加丁香园论坛讨论 >>

   作者: zhaochob


以下网友留言只代表网友个人观点,不代表网站观点



请输入验证码: